IL148180A0 - Isomeric fused pyrrolocarbazoles and isoindolones - Google Patents
Isomeric fused pyrrolocarbazoles and isoindolonesInfo
- Publication number
- IL148180A0 IL148180A0 IL14818000A IL14818000A IL148180A0 IL 148180 A0 IL148180 A0 IL 148180A0 IL 14818000 A IL14818000 A IL 14818000A IL 14818000 A IL14818000 A IL 14818000A IL 148180 A0 IL148180 A0 IL 148180A0
- Authority
- IL
- Israel
- Prior art keywords
- isoindolones
- fused pyrrolocarbazoles
- isomeric fused
- directed
- same
- Prior art date
Links
- XTBAPWCYTNCZTO-UHFFFAOYSA-N isoindol-1-one Chemical class C1=CC=C2C(=O)N=CC2=C1 XTBAPWCYTNCZTO-UHFFFAOYSA-N 0.000 title abstract 2
- QNMMYUBZGLXCCK-UHFFFAOYSA-N pyrrolo[3,2-a]carbazole Chemical class N1=C2C=CC=CC2=C2C1=C1C=CN=C1C=C2 QNMMYUBZGLXCCK-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
- Pyrrole Compounds (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15036799P | 1999-08-20 | 1999-08-20 | |
US09/640,825 US6399780B1 (en) | 1999-08-20 | 2000-08-17 | Isomeric fused pyrrolocarbazoles and isoindolones |
PCT/US2000/022724 WO2001014380A1 (en) | 1999-08-20 | 2000-08-18 | Isomeric fused pyrrolocarbazoles and isoindolones |
Publications (1)
Publication Number | Publication Date |
---|---|
IL148180A0 true IL148180A0 (en) | 2002-09-12 |
Family
ID=26847579
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14818000A IL148180A0 (en) | 1999-08-20 | 2000-08-18 | Isomeric fused pyrrolocarbazoles and isoindolones |
IL148180A IL148180A (en) | 1999-08-20 | 2002-02-14 | Pyrolocarbazoles and isoindulones are combined isomers and pharmaceuticals containing them |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL148180A IL148180A (en) | 1999-08-20 | 2002-02-14 | Pyrolocarbazoles and isoindulones are combined isomers and pharmaceuticals containing them |
Country Status (26)
Country | Link |
---|---|
US (4) | US6399780B1 (sk) |
EP (1) | EP1206473B1 (sk) |
JP (1) | JP4776842B2 (sk) |
KR (1) | KR100756686B1 (sk) |
CN (1) | CN1370173A (sk) |
AT (1) | ATE280172T1 (sk) |
AU (1) | AU776475C (sk) |
BG (1) | BG65545B1 (sk) |
BR (1) | BR0013811A (sk) |
CA (1) | CA2381885C (sk) |
CZ (1) | CZ2002616A3 (sk) |
DE (1) | DE60015153T2 (sk) |
EA (1) | EA005920B1 (sk) |
ES (1) | ES2230140T3 (sk) |
HK (1) | HK1046904B (sk) |
HU (1) | HUP0202758A3 (sk) |
IL (2) | IL148180A0 (sk) |
IS (1) | IS2186B (sk) |
MX (1) | MXPA02001789A (sk) |
NO (1) | NO323375B1 (sk) |
NZ (1) | NZ517174A (sk) |
PL (1) | PL354180A1 (sk) |
PT (1) | PT1206473E (sk) |
SK (1) | SK286805B6 (sk) |
TR (1) | TR200200474T2 (sk) |
WO (1) | WO2001014380A1 (sk) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6399780B1 (en) * | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
US7122679B2 (en) * | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
US7018999B2 (en) | 2001-05-16 | 2006-03-28 | Cephalon, Inc. | Methods for the treatment and prevention of pain |
EP1436279B8 (en) * | 2001-09-21 | 2008-10-29 | Smithkline Beecham Corporation | Chemical compounds |
SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
UA80447C2 (en) * | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
WO2005000194A2 (en) * | 2002-10-08 | 2005-01-06 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
RU2338555C2 (ru) | 2002-10-08 | 2008-11-20 | Ринат Ньюросайенс Корп. | Способы лечения послеоперационной боли введением антагониста фактора роста нервов и композиции, содержащие фактор роста нервов |
US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
EP1575517B1 (en) | 2002-12-24 | 2012-04-11 | Rinat Neuroscience Corp. | Anti-ngf antibodies and methods using same |
EP1594441B1 (en) | 2003-02-19 | 2010-12-15 | Rinat Neuroscience Corp. | Method for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same |
US7169802B2 (en) | 2003-12-23 | 2007-01-30 | Cephalon, Inc. | Fused pyrrolocarbazoles |
AU2005243247B2 (en) * | 2004-04-07 | 2012-03-01 | Regents Of The University Of Minnesota | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
US20060058250A1 (en) * | 2004-09-10 | 2006-03-16 | Cephalon, Inc. | Methods of treating proliferative skin diseases using carbazole derivatives |
WO2006034121A1 (en) * | 2004-09-17 | 2006-03-30 | Henry Ford Health System | Methods and compositions for use of angiogenesis inhibitors in the prevention and/or control of epilepsy |
ES2375735T3 (es) | 2005-02-04 | 2012-03-05 | Astrazeneca Ab | Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas. |
AU2006215386B2 (en) * | 2005-02-16 | 2009-06-11 | Astrazeneca Ab | Chemical compounds |
EP1853602B1 (en) * | 2005-02-16 | 2010-07-14 | AstraZeneca AB | Chemical compounds |
BRPI0610184A2 (pt) * | 2005-05-16 | 2012-09-25 | Astrazeneca Ab | composto, sal farmaceuticamente aceitável de um composto, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de cáncer e para a produção de um efeito anti-proliferativo em um animal de sanque quente, e, composição farmacêutica |
EP2388259A1 (en) * | 2005-10-28 | 2011-11-23 | AstraZeneca AB | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
EP2009005A4 (en) | 2006-04-19 | 2010-06-02 | Astellas Pharma Inc | AZOLECARBOXAMIDE DERIVATIVE |
US20080021013A1 (en) * | 2006-07-21 | 2008-01-24 | Cephalon, Inc. | JAK inhibitors for treatment of myeloproliferative disorders |
US20090326229A1 (en) * | 2006-08-02 | 2009-12-31 | Takeda Phamaceutical Company Limited | Alpha-carboline derivatives and methods for preparation thereof |
CA2668744C (en) * | 2006-11-17 | 2015-09-15 | Queen's University At Kingston | Compounds and methods for treating protein folding disorders |
WO2010131855A2 (ko) | 2009-05-13 | 2010-11-18 | 덕산하이메탈(주) | 오원자 헤테로고리를 포함하는 화합물 및 이를 이용한 유기전기소자, 그 단말 |
WO2008129255A1 (en) * | 2007-04-18 | 2008-10-30 | Astrazeneca Ab | 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer |
UA99459C2 (en) * | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
US20100204231A1 (en) * | 2007-05-04 | 2010-08-12 | Astrazeneca Ab | Amino-thiazolyl-pyrimidine derivatives and their use for the treatment of cancer |
EP2206707B1 (en) | 2007-10-24 | 2014-07-23 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
EP2292089A1 (en) | 2008-01-11 | 2011-03-09 | Astellas Pharma Inc. | Model animal having both pain in testis or testis-related discomfort actions and frequent urination |
CA2727073A1 (en) * | 2008-06-11 | 2009-12-17 | Astrazeneca Ab | Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders |
KR20110071098A (ko) * | 2008-09-30 | 2011-06-28 | 아스트라제네카 아베 | 복소환 jak 키나제 억제제 |
CA2742790C (en) | 2008-11-19 | 2018-02-13 | Cephalon, Inc. | Novel forms of an indazolo[5,4-a]pyrrolo [3,4-c] carbazole compound |
JP5390693B2 (ja) * | 2009-03-30 | 2014-01-15 | ドゥクサン ハイ メタル カンパニー リミテッド | 有機電子素子及びその化合物、端末 |
RS63063B1 (sr) | 2010-08-19 | 2022-04-29 | Zoetis Belgium S A | Anti-ngf antitela i njihova upotreba |
KR101497122B1 (ko) * | 2011-08-09 | 2015-03-06 | 덕산네오룩스 주식회사 | 2개 이상의 오원자 헤테로고리를 포함하는 화합물 및 이를 이용한 유기전기소자, 그 단말 |
TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物 |
WO2013184871A1 (en) | 2012-06-06 | 2013-12-12 | Zoetis Llc | Caninized anti-ngf antibodies and methods thereof |
KR101478884B1 (ko) | 2012-12-24 | 2015-01-05 | 충남대학교산학협력단 | 비스인돌일말레이미드계 화합물 및 이의 제조방법 |
US20200399250A1 (en) | 2017-11-23 | 2020-12-24 | Biomed X Gmbh | Pyrimidine Derivatives as Tropomyosin Receptor Kinase A (TRKA) Inhibitors |
WO2019177690A1 (en) | 2018-03-12 | 2019-09-19 | Zoetis Services Llc | Anti-ngf antibodies and methods thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816450A (en) | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
US4735939A (en) | 1987-02-27 | 1988-04-05 | The Dow Chemical Company | Insecticidal activity of staurosporine |
EP0303697B1 (en) | 1987-03-09 | 1997-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of physiologically active substance k-252 |
JPH07113027B2 (ja) | 1987-12-24 | 1995-12-06 | 協和醗酵工業株式会社 | K−252誘導体 |
FR2631199B1 (fr) | 1988-05-09 | 1991-03-15 | Centre Nat Rech Scient | Reacteur a plasma |
US5621101A (en) | 1992-07-24 | 1997-04-15 | Cephalon, Inc. | Protein kinase inhibitors for treatment of neurological disorders |
DK0699204T3 (da) | 1993-05-28 | 1999-02-22 | Cephalon Inc | Anvendelse af indolocarbazolderivater til behandling af en patologisk tilstand i prostata |
US5624949A (en) | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
US5545636A (en) | 1993-12-23 | 1996-08-13 | Eli Lilly And Company | Protein kinase C inhibitors |
CA2179650C (en) | 1993-12-23 | 2007-10-30 | William Francis Heath, Jr. | Bisindolemaleimides and their use as protein kinase c inhibitors |
GB9416467D0 (en) * | 1994-08-13 | 1994-10-05 | Wellcome Found | Compounds for use in medicine |
US5591855A (en) * | 1994-10-14 | 1997-01-07 | Cephalon, Inc. | Fused pyrrolocarbazoles |
US5705511A (en) * | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
US5475110A (en) * | 1994-10-14 | 1995-12-12 | Cephalon, Inc. | Fused Pyrrolocarbazoles |
US5594009A (en) * | 1994-10-14 | 1997-01-14 | Cephalon, Inc. | Fused pyrrolocarbazoles |
EP0776895B1 (en) | 1995-11-20 | 1998-10-14 | Eli Lilly And Company | Protein kinase C inhibitor |
US5808060A (en) * | 1995-12-11 | 1998-09-15 | Cephalon, Inc. | Fused isoindolones |
US5616724A (en) * | 1996-02-21 | 1997-04-01 | Cephalon, Inc. | Fused pyrrolo[2,3-c]carbazole-6-ones |
JP2000516250A (ja) | 1996-08-22 | 2000-12-05 | ブリストルーマイヤーズ スクイブ カンパニー | インドロピロロカルバゾールの細胞毒性アミノ糖および関連する糖誘導体 |
US6399780B1 (en) * | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
-
2000
- 2000-08-17 US US09/640,825 patent/US6399780B1/en not_active Expired - Lifetime
- 2000-08-18 MX MXPA02001789A patent/MXPA02001789A/es active IP Right Grant
- 2000-08-18 AT AT00954136T patent/ATE280172T1/de active
- 2000-08-18 EP EP00954136A patent/EP1206473B1/en not_active Expired - Lifetime
- 2000-08-18 JP JP2001518711A patent/JP4776842B2/ja not_active Expired - Fee Related
- 2000-08-18 ES ES00954136T patent/ES2230140T3/es not_active Expired - Lifetime
- 2000-08-18 CN CN00811850A patent/CN1370173A/zh active Pending
- 2000-08-18 CZ CZ2002616A patent/CZ2002616A3/cs unknown
- 2000-08-18 KR KR1020027002117A patent/KR100756686B1/ko not_active IP Right Cessation
- 2000-08-18 WO PCT/US2000/022724 patent/WO2001014380A1/en active IP Right Grant
- 2000-08-18 EA EA200200271A patent/EA005920B1/ru not_active IP Right Cessation
- 2000-08-18 AU AU66471/00A patent/AU776475C/en not_active Ceased
- 2000-08-18 IL IL14818000A patent/IL148180A0/xx active IP Right Grant
- 2000-08-18 HU HU0202758A patent/HUP0202758A3/hu unknown
- 2000-08-18 DE DE60015153T patent/DE60015153T2/de not_active Expired - Lifetime
- 2000-08-18 PT PT00954136T patent/PT1206473E/pt unknown
- 2000-08-18 NZ NZ517174A patent/NZ517174A/en unknown
- 2000-08-18 PL PL00354180A patent/PL354180A1/xx unknown
- 2000-08-18 SK SK246-2002A patent/SK286805B6/sk not_active IP Right Cessation
- 2000-08-18 BR BR0013811-8A patent/BR0013811A/pt not_active Application Discontinuation
- 2000-08-18 CA CA002381885A patent/CA2381885C/en not_active Expired - Fee Related
- 2000-08-18 TR TR2002/00474T patent/TR200200474T2/xx unknown
-
2002
- 2002-02-01 US US10/062,159 patent/US6635669B2/en not_active Expired - Lifetime
- 2002-02-12 IS IS6266A patent/IS2186B/is unknown
- 2002-02-14 IL IL148180A patent/IL148180A/en not_active IP Right Cessation
- 2002-02-19 NO NO20020809A patent/NO323375B1/no not_active IP Right Cessation
- 2002-02-21 BG BG106423A patent/BG65545B1/bg unknown
- 2002-11-20 HK HK02108409.6A patent/HK1046904B/zh not_active IP Right Cessation
-
2003
- 2003-04-24 US US10/422,164 patent/US6872746B2/en not_active Expired - Fee Related
-
2005
- 2005-01-05 US US11/029,330 patent/US7291732B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL148180A0 (en) | Isomeric fused pyrrolocarbazoles and isoindolones | |
MXPA02004415A (es) | Pirazolonas sustituidas con heterociclicas. | |
EA200100589A1 (ru) | Азабициклоалканы как модуляторы ccr5 | |
TR200101567T2 (tr) | Yeni triazolo(4.5-D)pirimidin bileşimleri. | |
AU4015697A (en) | Bicyclic pyrimidine derivatives and their use as anti-coagulants | |
BG66103B1 (bg) | Кондензирани пиролокарбазоли | |
EA200100588A1 (ru) | Пиперидины как модуляторы ccr5 | |
IL153406A0 (en) | Cyclopentanoindoles, compositions containing such compounds and methods of treatment | |
PL344475A1 (en) | Bridged indenopyrrolocarbazoles | |
EE05091B1 (et) | Oligosahhariidid, nende valmistamismeetod ja kasutamine ning farmatseutilised kompositsioonid | |
SG149045A1 (en) | Novel fused pyrrolocarbazoles | |
IL160171A0 (en) | Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
TR200002380T2 (tr) | Yeni triazolo (4,5-d) pirimidin bileşikleri | |
MXPA01008347A (es) | Compuestos quimicos. | |
AP2002002641A0 (en) | Estrogen agonist metabolites. | |
YU62504A (sh) | Triciklična 2-pirimidonska jedinjenja korisna kao inhibitori hiv reverzne transkriptoze | |
NO963331L (no) | 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister | |
EE200200326A (et) | Asendatud homopiperidüülbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon | |
MX9706927A (es) | Antagonistas biciclicos de taquicininas, preparacion de los mismos y su uso en composiciones farmaceuticas. | |
PL343546A1 (en) | Processes for preparing intermediates | |
ES8602676A1 (es) | Un procedimiento para la preparacion de nuevos derivados de pirrolo-(2,1-a)isoquilonina. | |
PT1196428E (pt) | Esteroides substituidos com 11 beta-aril-17, 17-espirotiolano | |
IL129727A0 (en) | 1-(3-Aminoindazol-5-YL)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors | |
AP1579A (en) | Novel 17-Halogenated 19-nor steroids, method and intermediates for preparing same, use as medicines and pharmaceutical compositions containing same. | |
AU7079300A (en) | Compositions and methods for the treatment of immune related diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |